Blood-Based Biomarkers for Prognosis and Diagnosis of Colorectal Cancer
Keywords:
Biomarker, Circulating tumor cells, Colorectal cancer, Colonoscopy, miRNAAbstract
Colorectal cancer (CRC) is a disease that mostly affects developing countries with its high incidence and mortality rates. Global burden of CRC is increasing, and early diagnosis of the disease affects the survival rate of patients. Current screening methods such as colonoscopy are inadequate because of invasive, high costs and a low participation rate. It is important to find a non-invasive, low cost and easily accessible test for CRC screening. Because of their high sensitivity and specificity, blood-based biomarkers have potential for early diagnosis and prognosis of CRC. The purpose of this review is to summarize candidate and currently used diagnostic and prognostic biomarkers for blood samples in patients with CRC.
References
Alix-Panabières, C., Pantel, K. (2014). Challenges in circulating tumour cell research. Nat. Rev. Cancer, 14(9), 623–631.
Arnold, M., Sierra, M.S., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut, 66(4), 683-691.
Board, R. E., Knight, L., Greystoke, A., Blackhall, F., Hughes, A., Dive, C., Ranson, M. (2008). DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark. Insights, 2, 307–319.
Carter, J.V., Galbraith, N.J., Yang, D., Burton, J.F., Walker, S.P., Galandi, S. (2017). Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br. J. Cancer, 116(6), 762–774.
Cheng, H., Zhang, L., Cogdell, D.E., Zheng, H., Schetter, A.J., Nykter, M., Harris, C.C., Chen, K., Hamilton, S.R., Zhang, W. (2011). Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One, 6(3), e17745.
Cortez, M.A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A.K., Calin, G.A. (2011). MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol., 8, 467-477.
DePrimo, S.E., Wong, L.M., Khatry, D.B., Nicholas, S.L., Manning, W.C., Smolich, B.D., O’Farrell, A.M., Cherrington, J.M. (2003). Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer, 3, 3.
Frattini, M., Gallino, G., Signoroni, S., Balestra, D., Battaglia, L., Sozzi, G., Leo, E., Pilotti, S., Pierotti, M. A. (2006). Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann. N.Y. Acad. Sci., 1075, 185-90.
Ganepola, G.A., Nizin, J., Rutledge, J.R., Chang, D.H. (2014). Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World. J. Gastrointest. Oncol., 6(4), 83-97.
Gonzalez-Pons, M., Cruz-Correa, M. (2015). Colorectal Cancer Biomarkers: Where Are We Now? BioMed Research International, dx.doi.org/10.1155/2015/149014.
Graham, L.D., Pedersen, S.K., Brown, G.S., Ho, T., Kassir, Z., Moynihan, A.T., Vizgoft, E.K., Dunne, R., Pimlott, L., Young, G.P., Lapointe, L.C., Molloy, P.L. (2011). Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes & Cancer, 2(8):829– 840.
Hao, T. B., Shi, W., Shen, X. J., Qi, J., Wu, X. H., Wu, Y., Tang, Y. Y., Ju, S. Q. (2014). Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer, 111(8), 1482–1489.
Hauptman, N., Glavač, D. (2017). Colorectal Cancer Blood-Based Biomarkers. Gastroenterol. Res. Pract., 2017, 2195361.
Herbst, A., Rahmig, K., Stieber, P., Philipp, A., Jung, A., Ofner, A., Crispin, A., Neumann, J., Lamerz, R., Kolligset, F.T. (2011). Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol., 106(6), 1110-1118.
Holten-Andersen, M. N., Christensen, I. J., Nielsen, H. J., Stephens, R.W., Jensen, V., Nielsen, O.H., Sørensen, S., Overgaard, J., Lilja, H., Harris, A., Murphy, G., Brünner, N. (2002). Total levels of tissue inhibitor ofmetalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin. Cancer Res., 8(1), 156–164.
Iacopetta, B., Grieu, F., Amanuel, B. (2010). Microsatellite instability in colorectal cancer. Asia Pac. J. Clin. Onco., 6(4), 260–269.
Kanaan, Z., Roberts, H., Eichenberger, M.R., Billeter, A., Ocheretner, G., Pan, J., Rai, S.N., Jorden, J., Williford, A., Galandiuk, S. (2013). A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann. Surg., 258(3), 400-408.
Krutovskikh, V.A., Herceg, Z. (2010). Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. Bioessays, 32(10), 894-904.
Lange, C. P. E., Campan, M., Hinoue, T., Schmitz, R.F., van der Meulen-de Jong, A.E., Slingerland, H., Kok, P.J.M.J., van Dijk, C.M., Weisenberger, D.J., Shen, H., Tollenaar, R.A.E.M., Laird, P.W. (2012). Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE, 7(11), e50266.
Lee, R.C., Feinbaum, R.L., Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843–854.
Lee, Y.S., Dutta, A. (2009). MicroRNAs in cancer. Annu. Rev. Pathol., 4, 199-227.
Leon, S. A., Shapiro, B., Sklaroff, D. M., Yaros, M. J. (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37(3), 646-50.
Leszinski, G., Lehner, J., Gezer, U., Holdenrieder, S. (2014). Increased DNA integrity in colorectal cancer. In Vivo, 28 (3), 299–303.
Ling, H., Spizzo, R., Atlasi, Y., Nicoloso, M., Shimizu, M., Redis, R.S., Nishida, N., Gafà, R., Song, J., Guo, Z., Ivan, C., Barbarotto, E., De Vries, I., Zhang, X., Ferracin, M. (2013). CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res., 23, 1446-1461.
Mandel, P., Metais, P. (1948). Les acides nucleiques du plasma sanguin chez l’homme. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 142, 241–243.
Marshall, K.W., Mohr, S., Khettabi, F.E., Nossova, N., Chao, S., Bao, W., Ma, J., Li, X.J., Liew, C.C. (2010) A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int. J. Cancer, 126, 1177-1186.
Mead, R., Duku, M., Bhandari, P., Cree, I. A. (2011). Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br. J. Cancer, 105(2), 239–245.
Millner, L. M., Linder, M. W., Valdes Jr, R. (2013). Circulating Tumor Cells: A Review of Present Methods and the Need to Identify Heterogeneous Phenotypes. Ann. Clin. Lab. Sci., 43(3), 295–304.
Mouliere, F., Robert, B., Peyrotte E.A., Del Rio, M., Ychou, M., Molina, F., Gongora, C. Thierry A.R. (2011). High fragmentation characterizes tumour-derived circulating DNA. PLoS One, 6(9), e23418.
Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A., Thierry, A.R. (2014). Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol. Oncol., 8(5), 927-41.
Ng, E.K., Chong, W.W., Jin, H., Lam, E.K., Shin, V.Y., Yu, J., Poon, T.C., Ng, S.S., Sung, J.J. (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut, 58, 1375-1381.
Schaaij-Visser, T.B., de Wit, M., Lam, S.W., Jiménez, C.R. (2013). The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim. Biophys. Acta., 1834, 2242-2258.
Siegel, R.L., Miller, K.D., Wagle, N.S., Jemal, A. (2023).Cancer statistics. C.A. Cancer J. Clin., 73(1), 17-48.
Slack, F.J. (2013). MicroRNAs regulate expression of oncogenes. Clin. Chem., 59(1), 325-326.
Tan, S.H., Ida, H., Lau, Q.C., Goh, B.C., Chieng, W.S., Loh, M., Ito, Y. (2007). Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep., 18(5), 1225-1230.
Thierry, A.R., El Messaoudi, S., Gahan, P.B., Anker, P., Stroun, M. (2016). Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev., 35(3), 347–376.
Toiyama, Y., Hur, K., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C.R., Goel, A. (2014). Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg., 259(4), 735-43.
Tsouma, A., Aggeli, C., Lembessis, P., Zografos, G.N., Korkolis, D.P., Pectasides, D., Skondra, M., Pissimissis, N., Tzonou, A., Koutsilieris, M. (2010). Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J. Gastroenterol., 16, 5965-5974.
Umetani, N., Kim, J., Hiramatsu, S., Reber, H. A., Hines, O. J., Bilchik, A. J., Hoonet, D. S. (2006). Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem., 52(6), 1062–1069.
Vu, T., Datta, P.K. (2017). Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers, 9(12), 171.
Wang, B., Zhang, Q. (2012). The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol., 138(10), 1659-1666.
Wang, Y., Long, Y., Xu Y. Guan, Z., Lian, P., Peng, J., Cai, S., Cai, G. (2014). Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer,”. Gastroenterol. Res. Pract., 2014, 436985.
Warren, J. D., Xiong, W., Bunker, A. M., Vaughn, C. P., Furtado, L. V., Roberts, W. L., Fang, J.C., Samowitz, W.S., Heichman, K.A. (2011). Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Medicine, 9, 133.
Wightman, B., Ha, I., Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75:855–862.
Yip, K.T., Das, P.K., Suria, D., Lim, C.R., Ng, G.H., Liew, C.C. (2010). A casecontrolled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J. Exp. Clin. Cancer Res., 29(1), 128.
Yokobori, T., Iinuma, H., Shimamura, T., Imoto, S., Sugimachi, K., Ishii, H, Iwatsuki, M., Ota, D., Ohkuma, M., Iwaya, T., Nishida, N., Kogo, R., Sudo, T., Tanaka, F., Shibata, K., Toh, H., Sato, T., Barnard, G.F., Fukagawa, T., Yamamoto, S., Nakanishi, H., Sasaki, S., Miyano, S., Watanabe, T., Kuwano, H., Mimori, K., Pantel, K., Mori M. (2013). Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res., 73(7), 2059- 2069.
Yörüker, E.E., Holdenrieder, S., Gezer, U. (2016). Bloodbased biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin. Chim. Acta., 455, 26-32.
Zhao, W., Song, M., Zhang, J., Kuerban, M., Wang, H. (2015). Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. International Journal of Clinical and Experimental Pathology, 8(11): 14131–14140.
